GU Cancers 2020 | ENERGIZE: chemo + nivo with/without linrod for bladder cancer

Guru Sonpavde

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines ENERGIZE (NCT03661320), a Phase III trial investigating the efficacy of neoadjuvant chemotherapy in combination with nivolumab (nivo) with or without linrodostat (linrod) followed by postsurgery nivolumab or nivolumab with linrodostat in cisplatin-eligible patients with muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter